NCRI Cancer CTU Group releases new guidelines
Collaboration between clinical trials units (CTUs), working in partnership with clinical investigators (CIs), and pharmaceutical company partners is a key aspect of UK clinical cancer research and has been a key contributor to the growth of clinical trial activity in cancer over the past decade. In order to expedite successful partnerships a consistent approach to collaboration is required. The NCRI Cancer CTU Group have recently produced a guidance document entitled Principles for Collaboration with Pharmaceutical Company Partners to define standard terms of collaboration and facilitate effective delivery of the UK cancer trials portfolio.
A complementary guideline, also produced by the NCRI Cancer CTU Group, which describes the principles and considerations around reasonable access to and sharing of trial data with pharmaceutical company partners is also available.